Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Week, 23 July – Digital Health Deals; SPACS; Novel Approach To Liquid Biopsy

Executive Summary

In this edition of Device Week, Medtech Insight’s Marion Webb reviews the huge number of digital health investments announced in 2021, including numerous SPAC deals. UK-based reporter Barnaby Pickering talks about Angle, a British liquid diagnostics company that has developed a novel approach to liquid diagnostics.

Listen to the podcast via the player below:

 

The archive of Device Week and the rest of Informa Pharma Intelligence’s podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn, Spotify Podcasts and via smart speakers if one of these platforms has been set up as your default podcast provider. 

 

Medtech Insight articles addressing topics discussed in this episode: (list relevant stories, with hyperlinked headlines):

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel